
Thursday, March 27, 2025 8:31:34 AM
In a secondary offering, there's generally no mandatory holding period for the stock. Investors can usually sell their shares freely after the offering, unless there are specific lock-up agreements in place.
Here's a more detailed explanation:
What is a Secondary Offering?
A secondary offering (also known as a follow-on offering) occurs when existing shareholders, rather than the company itself, sell a portion of their shares to the public.
No Mandatory Holding Period:
Unlike an IPO (Initial Public Offering) where there might be lock-up periods for insiders, secondary offerings typically do not impose any restrictions on when investors can sell their shares.
Lock-up Periods:
However, it's important to note that some secondary offerings may have lock-up periods, similar to those seen in IPOs, during which certain investors (like company insiders) are restricted from selling their shares for a specified period.
Timing of Secondary Offerings:
Secondary offerings can be announced and marketed within a few days, which is faster than the process for IPOs.
Dilutive vs. Non-Dilutive:
Secondary offerings can be either dilutive (where the company issues new shares, increasing the total number outstanding) or non-dilutive (where existing shareholders sell their shares, but the total number of outstanding shares remains the same).
Just my opinion, of course.
Recent CVM News
- CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market • Business Wire • 04/23/2025 12:30:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:15:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (US) • 04/14/2025 02:10:00 PM
- With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz • PR Newswire (Canada) • 04/14/2025 02:10:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/09/2025 05:00:21 PM
- New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses • Business Wire • 04/08/2025 01:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:51:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:49:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 01:46:47 PM
- CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients • Business Wire • 03/24/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2025 09:07:52 PM
- CEL-SCI Announces Closing of $2.5 Million Offering • Business Wire • 03/18/2025 08:05:00 PM
- CEL-SCI Announces Pricing of $2.5 Million Offering • Business Wire • 03/17/2025 07:24:00 PM
- CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine • Business Wire • 03/17/2025 12:00:00 PM
- CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial • Business Wire • 02/20/2025 01:00:00 PM
- CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks • Business Wire • 02/18/2025 01:30:00 PM
- CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer • Business Wire • 01/14/2025 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/13/2025 09:16:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:25:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:12:41 PM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM